Clinical, immunological, and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex. 1987

W A Carter, and D R Strayer, and I Brodsky, and M Lewin, and M G Pellegrino, and L Einck, and H F Henriques, and G L Simon, and D M Parenti, and R G Scheib

10 patients with the acquired immunodeficiency syndrome (AIDS), AIDS-related complex (ARC), or lymphadenopathy syndrome (LAS) were given 200-250 mg ampligen, a mismatched double-stranded (ds) RNA with in-vitro antiviral activity against human immunodeficiency virus (HIV), twice a week for up to 18 weeks, without side-effects or toxicity. In all 9 patients who were positive for HIV RNA in peripheral blood mononuclear cells before therapy, levels became undetectable between days 10 and 40 of the start of therapy. 6 of the 7 patients with ARC or LAS also showed a progressive reduction in HIV load as measured by co-culture assays. All 10 patients had augmentation of delayed-type hypersensitivity skin reactions. Other changes noted during ampligen therapy included an increase in or maintenance of numbers of helper-inducer T lymphocytes, improvements in HIV-related symptoms, rises in titre of neutralising antibodies against HIV, and restoration of proper functioning of the natural lymphocyte antiviral dsRNA-dependent (2'-5'-oligoadenylate/RNA-ase L) pathway. Thus, in the short term, ampligen seems to have the dual ability to restore immunological function and to control HIV replication.

UI MeSH Term Description Entries
D011070 Poly I-C Interferon inducer consisting of a synthetic, mismatched double-stranded RNA. The polymer is made of one strand each of polyinosinic acid and polycytidylic acid. Poly(I-C),Poly(rI).Poly(rC),Polyinosinic-Polycytidylic Acid,Polyinosinic-Polycytidylic Acid (High MW),Polyriboinosinic-Polyribocytidylic Acid,Polyribose Inosin-Cytidil,Inosin-Cytidil, Polyribose,Poly I C,Polyinosinic Polycytidylic Acid,Polyriboinosinic Polyribocytidylic Acid,Polyribose Inosin Cytidil
D011072 Poly U A group of uridine ribonucleotides in which the phosphate residues of each uridine ribonucleotide act as bridges in forming diester linkages between the ribose moieties. Polyuridylic Acids,Uracil Polynucleotides,Poly(rU),Acids, Polyuridylic,Polynucleotides, Uracil
D011131 Polyribonucleotides A group of 13 or more ribonucleotides in which the phosphate residues of each ribonucleotide act as bridges in forming diester linkages between the ribose moieties.
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000386 AIDS-Related Complex A prodromal phase of infection with the human immunodeficiency virus (HIV). Laboratory criteria separating AIDS-related complex (ARC) from AIDS include elevated or hyperactive B-cell humoral immune responses, compared to depressed or normal antibody reactivity in AIDS; follicular or mixed hyperplasia in ARC lymph nodes, leading to lymphocyte degeneration and depletion more typical of AIDS; evolving succession of histopathological lesions such as localization of Kaposi's sarcoma, signaling the transition to the full-blown AIDS. ARC,Lymphadenopathy Syndrome,AIDS Related Complex,Complex, AIDS-Related,Lymphadenopathy Syndromes,Syndrome, Lymphadenopathy,Syndromes, Lymphadenopathy
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D000956 Antigens, Viral Substances elaborated by viruses that have antigenic activity. Viral Antigen,Viral Antigens,Antigen, Viral
D012330 RNA, Double-Stranded RNA consisting of two strands as opposed to the more prevalent single-stranded RNA. Most of the double-stranded segments are formed from transcription of DNA by intramolecular base-pairing of inverted complementary sequences separated by a single-stranded loop. Some double-stranded segments of RNA are normal in all organisms. Double-Stranded RNA,Double Stranded RNA,RNA, Double Stranded

Related Publications

W A Carter, and D R Strayer, and I Brodsky, and M Lewin, and M G Pellegrino, and L Einck, and H F Henriques, and G L Simon, and D M Parenti, and R G Scheib
January 2002, Drugs in R&D,
W A Carter, and D R Strayer, and I Brodsky, and M Lewin, and M G Pellegrino, and L Einck, and H F Henriques, and G L Simon, and D M Parenti, and R G Scheib
January 1989, Journal of acquired immune deficiency syndromes,
W A Carter, and D R Strayer, and I Brodsky, and M Lewin, and M G Pellegrino, and L Einck, and H F Henriques, and G L Simon, and D M Parenti, and R G Scheib
January 1996, Experimental lung research,
W A Carter, and D R Strayer, and I Brodsky, and M Lewin, and M G Pellegrino, and L Einck, and H F Henriques, and G L Simon, and D M Parenti, and R G Scheib
January 2004, Drugs in R&D,
W A Carter, and D R Strayer, and I Brodsky, and M Lewin, and M G Pellegrino, and L Einck, and H F Henriques, and G L Simon, and D M Parenti, and R G Scheib
April 1989, AIDS research and human retroviruses,
W A Carter, and D R Strayer, and I Brodsky, and M Lewin, and M G Pellegrino, and L Einck, and H F Henriques, and G L Simon, and D M Parenti, and R G Scheib
December 1986, AIDS research,
W A Carter, and D R Strayer, and I Brodsky, and M Lewin, and M G Pellegrino, and L Einck, and H F Henriques, and G L Simon, and D M Parenti, and R G Scheib
June 1994, Journal of medical virology,
W A Carter, and D R Strayer, and I Brodsky, and M Lewin, and M G Pellegrino, and L Einck, and H F Henriques, and G L Simon, and D M Parenti, and R G Scheib
May 1986, Orvosi hetilap,
W A Carter, and D R Strayer, and I Brodsky, and M Lewin, and M G Pellegrino, and L Einck, and H F Henriques, and G L Simon, and D M Parenti, and R G Scheib
December 1988, Lancet (London, England),
W A Carter, and D R Strayer, and I Brodsky, and M Lewin, and M G Pellegrino, and L Einck, and H F Henriques, and G L Simon, and D M Parenti, and R G Scheib
May 1976, Biochemical and biophysical research communications,
Copied contents to your clipboard!